Sun-Novo(SH:688621) Zheng Quan Zhi Xing·2025-05-12 12:25Core Viewpoint - The company plans to acquire 100% equity of Jiangsu Langyan Life Technology Holdings Co., Ltd. through the issuance of shares and convertible bonds, which aligns with the regulations of the Shanghai Stock Exchange's Sci-Tech Innovation Board [2][4] Group 1: Industry Alignment - The target company operates in the "C27 Pharmaceutical Manufacturing" sector, which is upstream and downstream related to the company's business, thus meeting the Sci-Tech Innovation Board's positioning requirements [2][3] - According to the National Bureau of Statistics, the target company's industry falls under the "4.1.2 Chemical Drugs and Raw Materials Manufacturing" category within the "4 Biological Industry," qualifying it as part of the biopharmaceutical field [3] Group 2: Synergy Between Companies - The company specializes in comprehensive preclinical and clinical drug research services (CRO) and has a demand for self-developed products, while the target company focuses on high-end chemical drugs and raw materials, having established a mature pharmaceutical production system [3] - The acquisition will enable the company to leverage the target's complete pharmaceutical production capabilities, enhancing research efficiency and reducing costs, while optimizing production processes and ensuring quality [3] - This transaction is expected to maximize the commercial value of the company's proprietary products and create new profit growth points by combining the research advantages of the company with the production and sales strengths of the target [3]